$CVM
CEL SCI CORP Stock $cvm

$cvm Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000165495421008919 Filed on August 13, 2021

Income Statement

Concept	2021 Q3	2021 Q2	2020 Q3
Revenue	$0.00	$0.00	$28.56K
YoY Change	-100.0%	-100.0%	-62.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.183M	$3.274M	$3.314M
YoY Change	-3.94%	2.57%	225.67%
% of Gross Profit
Research & Development	$5.291M	$7.182M	$5.328M
YoY Change	-0.71%	80.95%	13.3%
% of Gross Profit
Depreciation & Amortization	$581.4K	$548.2K	$548.9K
YoY Change	5.93%	0.29%	355.49%
% of Gross Profit
Operating Expenses	$8.474M	$10.46M	$8.642M
YoY Change	-1.95%	46.01%	51.07%
Operating Profit		-$10.46M
YoY Change		50.12%
Interest Expense	$19.87K	$765.3K	$2.952M
YoY Change	-99.33%	-149.17%	39.99%
% of Operating Profit
Other Income/Expense, Net	$248.9K	$753.0K	$113.4K
YoY Change	119.54%	40714.09%	-108.63%
Pretax Income	-$8.205M	-$8.938M	-$5.548M
YoY Change	47.9%	-13.03%	14.43%
Income Tax
% Of Pretax Income
Net Earnings	-$8.205M	-$8.938M	-$5.548M
YoY Change	47.9%	-13.03%	14.43%
Net Earnings / Revenue			-19424.68%
Basic Earnings Per Share		-$0.22
Diluted Earnings Per Share	-$191.1K	-$0.25	-$144.7K
COMMON SHARES
Basic Shares Outstanding	43.03M shares	41.02M shares
Diluted Shares Outstanding		41.23M shares

Balance Sheet

Concept	2021 Q3	2021 Q2	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$42.21M	$47.11M	$15.51M
YoY Change	172.18%	133.95%	83.65%
Cash & Equivalents	$36.06M	$35.96M	$15.51M
Short-Term Investments	$6.151M	$11.15M
Other Short-Term Assets	$998.5K	$987.3K	$1.313M
YoY Change	-23.98%	-34.44%	150.2%
Inventory	$2.007M	$1.579M	$820.1K
Prepaid Expenses	$998.5K	$978.6K	$1.313M
Receivables	$54.92K	$54.92K	$54.92K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$45.27M	$49.73M	$17.70M
YoY Change	155.81%	119.23%	80.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.66M	$13.55M	$5.844M
YoY Change	133.81%	-29.59%	-63.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.911M	$1.911M	$1.671M
YoY Change	14.36%	14.36%	0.0%
Total Long-Term Assets	$30.60M	$1.900M	$1.700M
YoY Change	1699.91%	-91.05%	-90.45%
TOTAL ASSETS
Total Short-Term Assets	$45.27M	$49.73M	$17.70M
Total Long-Term Assets	$30.60M	$1.900M	$1.700M
Total Assets	$75.87M	$79.64M	$40.54M
YoY Change	87.16%	81.38%	46.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.676M	$2.144M	$2.023M
YoY Change	-17.16%	127.21%	27.52%
Accrued Expenses	$859.2K	$868.4K	$510.5K
YoY Change	68.3%	-1.68%	-31.37%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$600.0K	$500.0K	$900.0K
YoY Change	-33.33%	-44.44%
Total Short-Term Liabilities	$3.937M	$5.157M	$4.266M
YoY Change	-7.7%	10.87%	41.25%
LONG-TERM LIABILITIES
Long-Term Debt	$13.25M	$13.60M	$11.75M
YoY Change	12.76%	13.41%	-12.99%
Other Long-Term Liabilities	$125.0K	$125.0K	$125.0K
YoY Change	0.0%	-98.04%	-15.28%
Total Long-Term Liabilities	$125.0K	$125.0K	$125.0K
YoY Change	0.0%	-99.32%	-15.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.937M	$5.157M	$4.266M
Total Long-Term Liabilities	$125.0K	$125.0K	$125.0K
Total Liabilities	$19.34M	$19.85M	$20.81M
YoY Change	-7.08%	-13.78%	-7.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$418.2M	-$410.0M	-$381.8M
YoY Change	9.52%		7.95%
Common Stock	$432.1K	$429.6K	$387.3K
YoY Change	11.56%		9.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$56.53M	$59.79M	$19.73M
YoY Change
Total Liabilities & Shareholders Equity	$75.87M	$79.64M	$40.54M
YoY Change	87.16%	81.38%	46.75%

Cashflow Statement

Concept	2021 Q3	2021 Q2	2020 Q3
OPERATING ACTIVITIES
Net Income	-$8.205M	-$8.938M	-$5.548M
YoY Change	47.9%	-13.03%	14.43%
Depreciation, Depletion And Amortization	$581.4K	$548.2K	$548.9K
YoY Change	5.93%	0.29%	355.49%
Cash From Operating Activities	-$4.802M	-$5.200M	-$3.586M
YoY Change	33.91%	40.56%	-7.74%
INVESTING ACTIVITIES
Capital Expenditures	-$387.7K	-$2.000M	-$1.125M
YoY Change	-65.53%	148.86%	17308.36%
Acquisitions
YoY Change
Other Investing Activities	$4.977M	$0.00
YoY Change
Cash From Investing Activities	$4.590M	-$2.000M	-$1.125M
YoY Change	-508.12%	148.86%	2193.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	314.9K	36.73M	82.89K
YoY Change	279.95%	256.22%	-97.14%
NET CHANGE
Cash From Operating Activities	-4.802M	-5.200M	-3.586M
Cash From Investing Activities	4.590M	-2.000M	-1.125M
Cash From Financing Activities	314.9K	36.73M	82.89K
Net Change In Cash	102.4K	29.53M	-4.628M
YoY Change	-102.21%	408.47%	344.68%
FREE CASH FLOW
Cash From Operating Activities	-$4.802M	-$5.200M	-$3.586M
Capital Expenditures	-$387.7K	-$2.000M	-$1.125M
Free Cash Flow	-$4.414M	-$3.201M	-$2.462M
YoY Change	79.33%	10.52%	-36.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43028150	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35957715	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15508909	USD
CY2021Q2	us-gaap	Short Term Investments ShortTermInvestments	11152245	USD
CY2020Q3	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	54922	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	54922	USD
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	978575	USD
CY2020Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1313432	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	1579245	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	820052	USD
CY2021Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	8712	USD
CY2020Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	0	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	49731414	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	17697315	USD
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	13125302	USD
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	13811849	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1046648	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1198958	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13548079	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20136789	USD
	cvm	Finance Lease Obligation Included In Accounts Payable FinanceLeaseObligationIncludedInAccountsPayable	1328	USD
	cvm	Finance Lease Obligation Included In Accounts Payable FinanceLeaseObligationIncludedInAccountsPayable	775	USD
	cvm	Prepaid Consulting Services Paid With Issuance Of Common Stock PrepaidConsultingServicesPaidWithIssuanceOfCommonStock	292792	USD
	cvm	Prepaid Consulting Services Paid With Issuance Of Common Stock PrepaidConsultingServicesPaidWithIssuanceOfCommonStock	11706	USD
CY2020Q3	us-gaap	Assets Assets	40536454	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2144455	USD
	us-gaap	Operating Expenses OperatingExpenses	21070251	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27720493	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20540145	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5843993	USD
CY2021Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	279366	USD
CY2020Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	313422	USD
CY2021Q2	us-gaap	Deposit Assets DepositAssets	1910917	USD
CY2020Q3	us-gaap	Deposit Assets DepositAssets	1670917	USD
CY2021Q2	us-gaap	Assets Assets	79641726	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2023067	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	868443	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	510515	USD
CY2021Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	532620	USD
CY2020Q3	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	448022	USD
CY2021Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	918704	USD
CY2020Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	213787	USD
CY2021Q2	cvm	Lease Liabilities Current Portion LeaseLiabilitiesCurrentPortion	692478	USD
CY2020Q3	cvm	Lease Liabilities Current Portion LeaseLiabilitiesCurrentPortion	1070123	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5156700	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4265514	USD
CY2021Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2020Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3551826	USD
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	13603297	USD
CY2020Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	11753100	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	962985	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1114340	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	125000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	125000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	19847982	USD
CY2020Q3	us-gaap	Liabilities Liabilities	20809780	USD
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42963391	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38730150	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	429634	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	387302	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	469355665	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	401174675	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-409991555	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-381835303	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	59793744	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	19726674	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79641726	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40536454	USD
	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	530106	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17818373	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12680430	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9902120	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8389821	USD
	us-gaap	Operating Expenses OperatingExpenses	27720493	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28156252	USD
	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	1436473	USD
	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	774245	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-872457	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-777898	USD
CY2020Q2	cvm	Gain Loss On Derivatives Instruments GainLossOnDerivativesInstruments	-1282829	USD
CY2021Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Other Expenses OtherExpenses	38741	USD
	cvm	Gain Loss On Derivatives Instruments GainLossOnDerivativesInstruments	-991562	USD
	cvm	Gain Loss On Derivatives Instruments GainLossOnDerivativesInstruments	-3565347	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-24876157	USD
	cvm	Modification Of Warrants ModificationOfWarrants	-350861	USD
	cvm	Modification Of Warrants ModificationOfWarrants	-21734	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28507113	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24897891	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39907624	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.74
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40158321	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36230092	shares
CY2021Q2	us-gaap	Other Income OtherIncome	0	USD
CY2020Q2	us-gaap	Other Income OtherIncome	195874	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7182099	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3969070	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3274480	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3192403	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	10456579	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	7161473	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10456579	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6965599	USD
CY2020Q2	us-gaap	Other Expenses OtherExpenses	1845	USD
CY2021Q2	cvm	Gain Loss On Derivatives Instruments GainLossOnDerivativesInstruments	1116619	USD
CY2020Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-805753	USD
CY2021Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	761237	USD
CY2020Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-950935	USD
CY2021Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-351332	USD
CY2020Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-273708	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-8938268	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-10276979	USD
CY2021Q2	cvm	Modification Of Warrants ModificationOfWarrants	-265082	USD
CY2020Q2	cvm	Modification Of Warrants ModificationOfWarrants	0	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9203350	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10276979	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41020485	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37453539	shares
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41231082	shares
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37453539	shares
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	19726674	USD
CY2020Q4	cvm	Equity Based Compensation Employees Amount EquityBasedCompensationEmployeesAmount	3296309	USD
CY2020Q4	cvm	Proceeds From The Sale Of Common Stock Amount ProceedsFromTheSaleOfCommonStockAmount	13559500	USD
CY2020Q4	cvm	Warrant Exercises Amount WarrantExercisesAmount	89250	USD
CY2020Q4	cvm	Contributions Paid In Common Stock Amount ContributionsPaidInCommonStockAmount	41671	USD
CY2020Q4	cvm	Stock And Options Issued To Nonemployees For Service Amount StockAndOptionsIssuedToNonemployeesForServiceAmount	152450	USD
CY2020Q4	cvm	Options Exercises Amount OptionsExercisesAmount	23511	USD
CY2020Q4	cvm	Modification Of Warrants Amount ModificationOfWarrantsAmount	192	USD
CY2020Q4	cvm	Share Issuance Costs ShareIssuanceCosts	-117021	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-7936864	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28835672	USD
CY2021Q1	cvm	Warrant Exercises Amount WarrantExercisesAmount	7938841	USD
CY2021Q1	cvm	Equity Based Compensation Employees Amount EquityBasedCompensationEmployeesAmount	3282742	USD
CY2021Q1	cvm	Contributions Paid In Common Stock Amount ContributionsPaidInCommonStockAmount	51420	USD
CY2021Q1	cvm	Stock And Options Issued To Nonemployees For Service Amount StockAndOptionsIssuedToNonemployeesForServiceAmount	379277	USD
CY2021Q1	cvm	Options Exercises Amount OptionsExercisesAmount	138788	USD
CY2021Q1	cvm	Share Issuance Costs ShareIssuanceCosts	-13828	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-11281120	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	29331792	USD
CY2021Q2	cvm	Proceeds From The Sale Of Common Stock Amount ProceedsFromTheSaleOfCommonStockAmount	33803926	USD
CY2021Q2	cvm	Warrant Exercises Amount WarrantExercisesAmount	1379490	USD
CY2021Q2	cvm	Equity Based Compensation Employees Amount EquityBasedCompensationEmployeesAmount	3511359	USD
CY2021Q2	cvm	Contributions Paid In Common Stock Amount ContributionsPaidInCommonStockAmount	53205	USD
CY2021Q2	cvm	Stock And Options Issued To Nonemployees For Service Amount StockAndOptionsIssuedToNonemployeesForServiceAmount	267068	USD
CY2021Q2	cvm	Options Exercises Amount OptionsExercisesAmount	464162	USD
CY2021Q2	cvm	Modification Of Warrants Amount ModificationOfWarrantsAmount	24195	USD
CY2021Q2	cvm	Share Issuance Costs ShareIssuanceCosts	-103185	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-8938268	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	59793744	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	5133667	USD
CY2019Q4	cvm	Adoption Of New Accounting Standard AdoptionOfNewAccountingStandard	2146195	USD
CY2019Q4	cvm	Issuance Of Common Stock Amount IssuanceOfCommonStockAmount	5050003	USD
CY2019Q4	cvm	Warrant Exercises Amount WarrantExercisesAmount	297101	USD
CY2019Q4	cvm	Equity Based Compensation Employees Amount EquityBasedCompensationEmployeesAmount	1800225	USD
CY2019Q4	cvm	Contributions Paid In Common Stock Amount ContributionsPaidInCommonStockAmount	40937	USD
CY2019Q4	cvm	Stock Issued To Nonemployees For Service Amount StockIssuedToNonemployeesForServiceAmount	84447	USD
CY2019Q4	cvm	Purchase Of Stock By Officer Amount PurchaseOfStockByOfficerAmount	25000	USD
CY2019Q4	cvm	Share Issuance Costs ShareIssuanceCosts	-92150	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	8954065	USD
CY2020Q1	cvm	Proceeds From The Sale Of Common Stock Amount ProceedsFromTheSaleOfCommonStockAmount	7867629	USD
CY2020Q1	cvm	Warrant Exercises Amount WarrantExercisesAmount	4318706	USD
CY2020Q1	cvm	Equity Based Compensation Employees Amount EquityBasedCompensationEmployeesAmount	1780979	USD
CY2020Q1	cvm	Contributions Paid In Common Stock Amount ContributionsPaidInCommonStockAmount	38959	USD
CY2020Q1	cvm	Stock Issued To Nonemployees For Service Amount StockIssuedToNonemployeesForServiceAmount	235024	USD
CY2020Q1	cvm	Purchase Of Stock By Officers And Directors Amount PurchaseOfStockByOfficersAndDirectorsAmount	159990	USD
CY2020Q1	cvm	Options Exercises Amount OptionsExercisesAmount	49898	USD
CY2020Q1	cvm	Share Issuance Costs ShareIssuanceCosts	-199372	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-9067818	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	14138060	USD
CY2020Q2	cvm	Proceeds From The Sale Of Common Stock Amount ProceedsFromTheSaleOfCommonStockAmount	1074807	USD
CY2020Q2	cvm	Warrant Exercises Amount WarrantExercisesAmount	10156275	USD
CY2020Q2	cvm	Equity Based Compensation Employees Amount EquityBasedCompensationEmployeesAmount	3109127	USD
CY2020Q2	cvm	Contributions Paid In Common Stock Amount ContributionsPaidInCommonStockAmount	42895	USD
CY2020Q2	cvm	Stock Issued To Nonemployees For Service Amount StockIssuedToNonemployeesForServiceAmount	205381	USD
CY2020Q2	cvm	Shares Issued For Settlement Of Clinical Research Costs Amount SharesIssuedForSettlementOfClinicalResearchCostsAmount	1769500	USD
CY2020Q2	cvm	Options Exercises Amount OptionsExercisesAmount	276415	USD
CY2020Q2	cvm	Modification Of Warrants Amount ModificationOfWarrantsAmount	5554	USD
	cvm	Property Plant Equipment Included In Current Liabilities PropertyPlantEquipmentIncludedInCurrentLiabilities	121441	USD
	cvm	Capitalizable Patent Costs Included In Current Liabilities CapitalizablePatentCostsIncludedInCurrentLiabilities	20000	USD
CY2020Q2	cvm	Warrant Issuances WarrantIssuances	805753	USD
CY2020Q2	cvm	Share Issuance Costs ShareIssuanceCosts	-418497	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-10276979	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	20888291	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28156252	USD
	us-gaap	Net Income Loss NetIncomeLoss	-24876157	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1649699	USD
	cvm	Shares Issued For Settlement Of Clinical Research Costs SharesIssuedForSettlementOfClinicalResearchCosts	1769500	USD
	cvm	Short Term Investment ShortTermInvestment	-6578	USD
	cvm	Short Term Investment ShortTermInvestment	0	USD
	cvm	Loss On Derivatives Instruments LossOnDerivativesInstruments	991562	USD
	cvm	Loss On Derivatives Instruments LossOnDerivativesInstruments	3565347	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1610855	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	955900	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	623146	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10090410	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6690331	USD
	cvm	Common Stock Contributed To Employee Benefit Plan CommonStockContributedToEmployeeBenefitPlan	146296	USD
	cvm	Net Purchases Of Us Treasury Bills NetPurchasesOfUSTreasuryBills	11145667	USD
	cvm	Net Purchases Of Us Treasury Bills NetPurchasesOfUSTreasuryBills	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8628648	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1530327	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	39975	USD
	cvm	Common Stock Contributed To Employee Benefit Plan CommonStockContributedToEmployeeBenefitPlan	122791	USD
	cvm	Shares Issued For Settlement Of Clinical Research Costs SharesIssuedForSettlementOfClinicalResearchCosts	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	805753	USD
	cvm	Modification Of Warrant ModificationOfWarrant	24387	USD
	cvm	Modification Of Warrant ModificationOfWarrant	5554	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	0	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-192242	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	232752	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-969219	USD
	cvm	Supplies Used For Rd And Manufacturing SuppliesUsedForRDAndManufacturing	-759193	USD
	cvm	Supplies Used For Rd And Manufacturing SuppliesUsedForRDAndManufacturing	-4648	USD
	cvm	Short Term Deposits ShortTermDeposits	-248712	USD
	cvm	Short Term Deposits ShortTermDeposits	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	689812	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-761675	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	297928	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	87820	USD
	us-gaap	Increase Decrease In Due To Officers And Stockholders IncreaseDecreaseInDueToOfficersAndStockholders	84598	USD
	us-gaap	Increase Decrease In Due To Officers And Stockholders IncreaseDecreaseInDueToOfficersAndStockholders	-166310	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	22459	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-815	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13984932	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11689969	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19774315	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1570302	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47363426	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13992439	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	207673	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	695447	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	184990	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6195571	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12063070	USD
	cvm	Proceeds From Landlord Funding Of Leasehold Improvements ProceedsFromLandlordFundingOfLeaseholdImprovements	1613546	USD
	cvm	Proceeds From Landlord Funding Of Leasehold Improvements ProceedsFromLandlordFundingOfLeaseholdImprovements	0	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	756817	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	592766	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54208053	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24952286	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	20448806	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11692015	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15508909	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8444774	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35957715	USD
	cvm	Property Plant Equipment Included In Current Liabilities PropertyPlantEquipmentIncludedInCurrentLiabilities	589400	USD
	cvm	Financing Costs Included In Current Liabilities FinancingCostsIncludedInCurrentLiabilities	76860	USD
	cvm	Financing Costs Included In Current Liabilities FinancingCostsIncludedInCurrentLiabilities	30152	USD
	us-gaap	Interest Paid Net InterestPaidNet	876779	USD
	us-gaap	Interest Paid Net InterestPaidNet	872710	USD
	cvm	Capitalizable Patent Costs Included In Current Liabilities CapitalizablePatentCostsIncludedInCurrentLiabilities	0	USD
	cvm	Changes To Right Of Use Assets And Liabilities ChangesToRightOfUseAssetsAndLiabilities	551444	USD
	cvm	Changes To Right Of Use Assets And Liabilities ChangesToRightOfUseAssetsAndLiabilities	399032	USD
	cvm	Accrued Consulting Services To Be Paid With Issuance Of Common Stock AccruedConsultingServicesToBePaidWithIssuanceOfCommonStock	110000	USD
	cvm	Accrued Consulting Services To Be Paid With Issuance Of Common Stock AccruedConsultingServicesToBePaidWithIssuanceOfCommonStock	110000	USD
	cvm	Fair Value Of Warrants Liabilities On Date Of Exercise FairValueOfWarrantsLiabilitiesOnDateOfExercise	3838471	USD
	cvm	Fair Value Of Warrants Liabilities On Date Of Exercise FairValueOfWarrantsLiabilitiesOnDateOfExercise	3035325	USD
CY2020Q3	cvm	Total Fair Value Of Derivative Liabilities TotalFairValueOfDerivativeLiabilities	3765613	USD
	cvm	Gain Loss Series V Warrants GainLossSeriesVWarrants	185652	USD
	cvm	Gain Loss Series W Warrants GainLossSeriesWWarrants	73570	USD
	cvm	Gain Loss Series W Warrants GainLossSeriesWWarrants	-614696	USD
CY2020Q3	cvm	Fair Value Of Series Zwarrants FairValueOfSeriesZwarrants	1207902	USD
CY2020Q3	cvm	Fair Value Of Series Zz Warrants FairValueOfSeriesZzWarrants	75044	USD
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Derivative Instruments</em> – The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim and annual reporting period. </p>
CY2021Q2	cvm	Fair Value Of Series Aa Warrants FairValueOfSeriesAaWarrants	263818	USD
	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">B. <span style="text-decoration:underline">OPERATIONS AND FINANCING</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On June 28, 2021, the Company announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine® (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The Phase 3 results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), which is about a 29% improvement, control arm 48.6%, Multikine arm 62.7% survival.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The study used the standard of care treatment for advanced primary head and neck cancer patients as a comparison. The patients received surgery followed by either radiation or chemoradiation (chemotherapy and radiation at the same time), as determined by the physician. This means that there were 2 treatment arms, 1) surgery plus radiation or 2) surgery plus chemoradiation. The arm that received Multikine treatment followed by surgery and radiation showed great survival benefit, but when chemotherapy was added in the second treatment arm, the immunological effect of Multikine was negated. Therefore when the two treatment arms were combined the study did not achieve its primary endpoint of a 10% improvement in overall survival. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">However, the analysis of the separate treatment arms was prespecified in the protocol and carried out prior to the Company becoming unblinded. The OS benefit of 14.1% at 5 years for this treatment arm exceeded the 10% OS benefit set out for the study population as a whole. The OS results for this treatment arm are significant (two-sided p=0.0236, HR=0.68) and the effect is robust, durable and increasing over time. The results from the Phase 3 cancer study proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this the Company will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population of about 210,000 patients annually worldwide.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and upgrade of laboratory facilities and clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company may be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings and warrant exercises similar to the way it has substantially funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">If the Company needs to raise capital, Management plans to raise additional capital in the form of warrant exercises, corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until it is able to raise the required funding. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impact of COVID-19 Pandemic</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In response to the global outbreak of COVID-19 and the World Health Organization’s classification of the outbreak as a pandemic, the Company continues to take the necessary precautions to ensure the safety of its employees and to minimize interruptions to its operations. Management follows the Centers for Disease Control and Prevention’s (“CDC”) guidance and the recommendations and restrictions provided by state and local authorities. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude of impact the pandemic will have on the Company’s financial condition, liquidity and future results of operations. Management is actively monitoring the risks to public health and the impact of overall global business activity on its financial condition, liquidity, operations, suppliers, industry, and workforce.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The financial statements have been prepared assuming the Company will continue as a going concern, but due to the Company’s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1400000	shares
CY2021Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	22.62
	cvm	Aggregate Net Proceeds AggregateNetProceeds	29400000	USD
	cvm	Additional Shares Of Common Stock AdditionalSharesOfCommonStock	210000	shares
	cvm	Additional Net Proceeds AdditionalNetProceeds	4400000	USD
	cvm	Schedule Stock Options Stock Bonuses And Compensation Granted By Company ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Shares Reserved <br/>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares Reserved for Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares <br/>Issued</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Remaining Options/Shares </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Under Plans</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Options Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,829</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,001,880</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">404,826</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">358,118</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">425,609</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,695</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">464,895</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">614,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2021Q2	cvm	Fair Value Of Series Bb Warrants FairValueOfSeriesBbWarrants	16696	USD
CY2020Q3	cvm	Fair Value Of Series Bb Warrants FairValueOfSeriesBbWarrants	65173	USD
CY2021Q2	cvm	Fair Value Of Series Cc Warrants FairValueOfSeriesCcWarrants	206978	USD
CY2020Q3	cvm	Fair Value Of Series Cc Warrants FairValueOfSeriesCcWarrants	1259712	USD
CY2021Q2	cvm	Fair Value Of Series Hh Warrants FairValueOfSeriesHhWarrants	1216	USD
CY2020Q3	cvm	Fair Value Of Series Hh Warrants FairValueOfSeriesHhWarrants	2000	USD
CY2020Q3	cvm	Fair Value Of Series Aa Warrants FairValueOfSeriesAaWarrants	1082212	USD
CY2021Q2	cvm	Total Fair Value Of Derivative Liabilities TotalFairValueOfDerivativeLiabilities	918704	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2603500	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	126954	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	42166	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	9374	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2595500	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	72809	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	9307	shares
	us-gaap	Dividends Share Based Compensation DividendsShareBasedCompensation	64000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	10090410	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	6690331	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	955900	USD
CY2021Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3511359	USD
CY2020Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3109127	USD
CY2021Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	403236	USD
CY2020Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	275919	USD
CY2021Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	1116619	USD
CY2020Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-1282829	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.75
	cvm	Schedule Of Derivative Liabilities Warrants And Other Options ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Warrant/Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Issue Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares Issuable upon Exercise </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>of Warrants/ Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Expiration Date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td/><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Reference</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2022 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6/11/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1/13/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2/15/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/26/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/22/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5/23/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">11/23/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/8/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">41,345</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/8/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2/23/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/16/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/26/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/22/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6/22/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333,432</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">7/24/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,838</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10/30/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">251,761</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">12/19/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">220,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/18/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2/5/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,868</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">7/28/2017 – </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/18/2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2.18 -</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$11.61</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">11/17/2022 </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">- 7/27/2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
	cvm	Schedule Of Fair Value Of Warrant Liabilitestabletextblock ScheduleOfFairValueOfWarrantLiabilitestabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,570</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">429,996</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,207,902</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">75,044</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">263,818</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,082,212</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB warrants </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,696</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,173</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">206,978</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,259,712</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,216</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total warrant liabilities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">918,704</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">3,765,613</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2020Q3	cvm	Fair Value Of Series W Warrants FairValueOfSeriesWWarrants	73570	USD
CY2021Q2	cvm	Fair Value Of Series Zwarrants FairValueOfSeriesZwarrants	429996	USD
	cvm	Gain Loss Series Z Warrants GainLossSeriesZWarrants	-113094	USD
	cvm	Gain Loss Series Z Warrants GainLossSeriesZWarrants	-742495	USD
	cvm	Gain Loss Series Zz Warrants GainLossSeriesZzWarrants	-98692	USD
	cvm	Gain Loss Series Zz Warrants GainLossSeriesZzWarrants	-38319	USD
	cvm	Gain Loss Series Aa Warrants GainLossSeriesAaWarrants	-306606	USD
	cvm	Gain Loss Series Aa Warrants GainLossSeriesAaWarrants	-547454	USD
	cvm	Gain Loss Series Bb Warrants GainLossSeriesBbWarrants	48477	USD
	cvm	Gain Loss Series Bb Warrants GainLossSeriesBbWarrants	-44620	USD
	cvm	Gain Loss Series Cc Warrants GainLossSeriesCcWarrants	-596001	USD
	cvm	Gain Loss Series Cc Warrants GainLossSeriesCcWarrants	-1245627	USD
	cvm	Gain Loss Series Ff Warrants GainLossSeriesFfWarrants	-319706	USD
	cvm	Gain Loss Series Hh Warrants GainLossSeriesHhWarrants	784	USD
	cvm	Gain Loss Series Hh Warrants GainLossSeriesHhWarrants	-35024	USD
	cvm	Gain Loss Series Jj Warrants GainLossSeriesJjWarrants	-64992	USD
	cvm	Gain Loss Series Ll Warrants GainLossSeriesLlWarrants	-98066	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-991562	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-3565347	USD
CY2020Q2	cvm	Gain Loss Series V Warrants GainLossSeriesVWarrants	107191	USD
CY2020Q2	cvm	Gain Loss Series W Warrants GainLossSeriesWWarrants	-247327	USD
CY2021Q2	cvm	Gain Loss Series Z Warrants GainLossSeriesZWarrants	583404	USD
CY2020Q2	cvm	Gain Loss Series Z Warrants GainLossSeriesZWarrants	-430619	USD
CY2020Q2	cvm	Gain Loss Series Zz Warrants GainLossSeriesZzWarrants	-33734	USD
CY2021Q2	cvm	Gain Loss Series Aa Warrants GainLossSeriesAaWarrants	355215	USD
CY2020Q2	cvm	Gain Loss Series Aa Warrants GainLossSeriesAaWarrants	-220831	USD
CY2021Q2	cvm	Gain Loss Series Bb Warrants GainLossSeriesBbWarrants	64678	USD
CY2020Q2	cvm	Gain Loss Series Bb Warrants GainLossSeriesBbWarrants	-37592	USD
CY2021Q2	cvm	Gain Loss Series Cc Warrants GainLossSeriesCcWarrants	199256	USD
CY2020Q2	cvm	Gain Loss Series Cc Warrants GainLossSeriesCcWarrants	-419350	USD
CY2021Q2	cvm	Gain Loss Series Hh Warrants GainLossSeriesHhWarrants	1228	USD
CY2020Q2	cvm	Gain Loss Series Hh Warrants GainLossSeriesHhWarrants	-567	USD
	cvm	Net Gain NetGain	107000	USD
CY2021Q2	cvm	Warrants Exercised WarrantsExercised	24200	shares
CY2021Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	289000	USD
	cvm	Warrants Exercised WarrantsExercised	306498	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3275490	USD
CY2020Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	9269755	USD
CY2020Q2	cvm	Warrants Exercised WarrantsExercised	674164	shares
	cvm	Warrants Exercised WarrantsExercised	908180	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	10298752	USD
	cvm	Warrants Shares WarrantsShares	461953	shares
	cvm	Warrants Amount WarrantsAmount	629000	USD
CY2021Q2	cvm	Equity Warrants Exercised EquityWarrantsExercised	413112	shares
CY2021Q2	cvm	Proceeds From Equity Warrant Exercises ProceedsFromEquityWarrantExercises	843204	USD
	cvm	Equity Warrants Exercised EquityWarrantsExercised	1137053	shares
	cvm	Proceeds From Equity Warrant Exercises ProceedsFromEquityWarrantExercises	2293620	USD
CY2020Q2	cvm	Equity Warrants Exercised EquityWarrantsExercised	175681	shares
CY2020Q2	cvm	Proceeds From Equity Warrant Exercises ProceedsFromEquityWarrantExercises	397730	USD
	cvm	Equity Warrants Exercised EquityWarrantsExercised	636665	shares
	cvm	Proceeds From Equity Warrant Exercises ProceedsFromEquityWarrantExercises	1438005	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.65
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1436473	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	2539245	USD
CY2021Q2	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	761237	USD
	cvm	Proceeds From Issuance Of Common Stocks ProceedsFromIssuanceOfCommonStocks	0	USD
CY2020Q2	cvm	Proceeds From Issuance Of Common Stocks ProceedsFromIssuanceOfCommonStocks	1769500	USD
CY2021Q2	cvm	Proceeds From Issuance Of Common Stocks ProceedsFromIssuanceOfCommonStocks	0	USD
	cvm	Proceeds From Issuance Of Common Stocks ProceedsFromIssuanceOfCommonStocks	1769500	USD
	cvm	Other Nonoperating Gains Loss OtherNonoperatingGainsLoss	1436473	USD
	cvm	Other Nonoperating Gains Loss OtherNonoperatingGainsLoss	769745	USD
CY2021Q2	cvm	Other Nonoperating Gains Loss OtherNonoperatingGainsLoss	761237	USD
CY2020Q2	cvm	Other Nonoperating Gains Loss OtherNonoperatingGainsLoss	-950935	USD
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14000	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3765613	USD
CY2019Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	6488310	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales	-3838471	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales	-3071775	USD
	cvm	Fair Value Measured On Recurring Basis Gain Loss Included Earnings FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings	991562	USD
CY2020	cvm	Fair Value Measured On Recurring Basis Gain Loss Included Earnings FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings	349078	USD
CY2021Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	918704	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3765613	USD
	cvm	Clinical Service Trial ClinicalServiceTrial	12000000	USD
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	34800000	USD
	cvm	Net Of Discount NetOfDiscount	11700000	USD
	us-gaap	Description Of Lessee Leasing Arrangements Capital Leases DescriptionOfLesseeLeasingArrangementsCapitalLeases	The revised rate upon adoption of ASC 842 was calculated to be 10.19% compared to the previously used rate of 8.80%, and the revised rate for the lease modification was calculated to be 8.45% compared to the previous rate of 10.00%.
	cvm	Change In Operating Lease Right Of Use Of Assets ChangeInOperatingLeaseRightOfUseOfAssets	712000	USD
	cvm	Increase Decrease In Operating Leases Net Income Loss IncreaseDecreaseInOperatingLeasesNetIncomeLoss	29000	USD
	cvm	Increase Decrease In Lease Right Of Use Of Assets And Liability IncreaseDecreaseInLeaseRightOfUseOfAssetsAndLiability	500000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	27000	USD
CY2021Q2	cvm	Finance Lease Right Of Use Assets FinanceLeaseRightOfUseAssets	13100000	USD
CY2020Q3	cvm	Finance Lease Right Of Use Assets FinanceLeaseRightOfUseAssets	13800000	USD
CY2021Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	14100000	USD
CY2020Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	12700000	USD
CY2021Q2	cvm	Current Balance CurrentBalance	500000	USD
CY2020Q3	cvm	Current Balance CurrentBalance	900000	USD
	cvm	Cash Paid Related To Finance Leases CashPaidRelatedToFinanceLeases	1600000	USD
	cvm	Cash Paid Related To Finance Leases Interest CashPaidRelatedToFinanceLeasesInterest	900000	USD
CY2021Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0845	pure
	cvm	Maturity Years MaturityYears	P7Y3M18D
CY2021Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	1900000	USD
CY2020Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	1700000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	13000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	48000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	38000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	31000	USD
CY2021Q2	cvm	Finance Lease Liability Payments Due Remainder Of Year FinanceLeaseLiabilityPaymentsDueRemainderOfYear	-182000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2486000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2569000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	2648000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	2733000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	2824000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	6186000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	19264000	USD
CY2021Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	5126000	USD
CY2021Q2	cvm	Net Present Value Of Lease Finance Lease Obligations NetPresentValueOfLeaseFinanceLeaseObligations	14138000	USD
CY2021Q2	cvm	Net Book Value Operating Lease Right Of Use Assets NetBookValueOperatingLeaseRightOfUseAssets	1000000.0	USD
CY2020Q3	cvm	Net Book Value Operating Lease Right Of Use Assets NetBookValueOperatingLeaseRightOfUseAssets	1200000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1100000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1300000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2020Q3	cvm	Finance Lease Obligations Net Of Current Portion FinanceLeaseObligationsNetOfCurrentPortion	100000	USD
CY2021Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	66000	USD
CY2020Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	67000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	176000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	198000	USD
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	64000	USD
CY2020Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	66000	USD
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.102	pure
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y10M24D
CY2021Q2	cvm	Lessee Operating Lease Liability Payments Due Remainder Of Year LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear	66000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	267000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	275000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	281000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	288000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	207000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	80000	USD
CY2021Q2	cvm	Lessee Operating Lease Liability Payments LesseeOperatingLeaseLiabilityPayments	1464000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	344000	USD
CY2021Q2	cvm	Cfgh cfgh	1120000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	39000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	40000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	28000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	24000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	97000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	279000	USD
	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-28507113	USD
	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-24897891	USD
CY2021Q2	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-9203350	USD
CY2020Q2	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-10276979	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39907624	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36230992	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41020485	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37453539	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28507113	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24897891	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9203350	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10276979	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1236514	USD
CY2021Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1233597	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-29743627	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24897891	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10436947	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10276979	USD
	cvm	Incremental Shares Underlying Dilutivein The Money Warrants IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants	250697	shares
CY2021Q2	cvm	Incremental Shares Underlying Dilutivein The Money Warrants IncrementalSharesUnderlyingDilutiveinTheMoneyWarrants	210597	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40158321	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36230992	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41231082	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37453539	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7145670	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7963591	shares

Files In Submission

Name	View Source	Status
0001654954-21-008919-index-headers.html	Edgar Link	pending
0001654954-21-008919-index.html	Edgar Link	pending
0001654954-21-008919.txt	Edgar Link	pending
0001654954-21-008919-xbrl.zip	Edgar Link	pending
cvm-20210630.xsd	Edgar Link	pending
cvm-20210630_cal.xml	Edgar Link	unprocessable
cvm-20210630_def.xml	Edgar Link	unprocessable
cvm-20210630_lab.xml	Edgar Link	unprocessable
cvm-20210630_pre.xml	Edgar Link	unprocessable
cvm_10q.htm	Edgar Link	pending
cvm_10q_htm.xml	Edgar Link	completed
cvm_ex31.htm	Edgar Link	pending
cvm_ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVM
CEL SCI CORP Stock $cvm

2021 Q3 Form 10-Q Financial Statement

#000165495421008919 Filed on August 13, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVM CEL SCI CORP Stock $cvm

2021 Q3 Form 10-Q Financial Statement

#000165495421008919 Filed on August 13, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVM
CEL SCI CORP Stock $cvm